36 related articles for article (PubMed ID: 33147530)
1. Pan-cancer landscape of homologous recombination deficiency.
Nguyen L; W M Martens J; Van Hoeck A; Cuppen E
Nat Commun; 2020 Nov; 11(1):5584. PubMed ID: 33149131
[TBL] [Abstract][Full Text] [Related]
2. A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene increases the risk of endometrial carcinoma.
Zhao J; Zhao T
J Obstet Gynaecol; 2022 Oct; 42(7):3299-3303. PubMed ID: 36006023
[TBL] [Abstract][Full Text] [Related]
3. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract][Full Text] [Related]
5. PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China.
Zhou RM; Li Y; Wang N; Niu CX; Huang X; Cao SR; Huo XR
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2987-2992. PubMed ID: 33112558
[TBL] [Abstract][Full Text] [Related]
6. PARP1 rs1136410 C/C genotype associated with an increased risk of esophageal cancer in smokers.
Zhou R; Li Y; Wang N; Niu C; Huang X; Cao S; Huo X
Mol Biol Rep; 2021 Feb; 48(2):1485-1491. PubMed ID: 33528729
[TBL] [Abstract][Full Text] [Related]
7. A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene is associated with platinum-based chemotherapeutic response and prognosis in epithelial ovarian cancer patients.
Zhao J; Wu J; Zuo W; Kang S; Li Y
Eur J Obstet Gynecol Reprod Biol; 2020 Dec; 255():183-189. PubMed ID: 33147530
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
Moore KN; Pothuri B
Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
[TBL] [Abstract][Full Text] [Related]
12. The systemic treatment of recurrent ovarian cancer revisited.
Baert T; Ferrero A; Sehouli J; O'Donnell DM; González-Martín A; Joly F; van der Velden J; Blecharz P; Tan DSP; Querleu D; Colombo N; du Bois A; Ledermann JA
Ann Oncol; 2021 Jun; 32(6):710-725. PubMed ID: 33675937
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
